论文部分内容阅读
目的:建立新化合物RY10-4在大鼠血浆中的HPLC分析方法,并采用该方法研究RY10-4在大鼠体内的药动学.方法:以甲醇:0.2％磷酸水溶液体系作为RY10-4的HPLC-UV检测流动相.首先采用50％磷酸-乙酸乙酯进行萃取,辅以涡旋,离心等操作从血液中提取出目的化合物.而后以芹菜素为内标进行专属性、线性、精密度、回收率等方法验证.最后以SD大鼠为动物模型,绘制药-时曲线,并用DAS 2.1.1进行分析.结果:所建立的HPLC方法以及血浆样品处理方法,均可满足实验要求.DAS软件计算显示,RY10-4符合二室模型和一级药动学.RY10-4主要通过中央室消除,而不是通过周围室的扩散消除.高浓度的RY10-4易产生积蓄,延缓药物消除.结论:RY10-4的HPLC检测方法条件温和,适用性强.药动学显示RY10-4血药浓度达峰和消除都较快,在高浓度下易引起蓄积作用.“,”Objective: To establish an HPLC analytical method of a new compound RY10-4, and evaluate its pharmacokinetics in rats. Methods: The concentrations of RY10-4 were determined by HPLC-UV with mobile phase consisting of methanol-water ( containing 0. 2％ phosphoric acid). The plasma samples were extracted by50％ phosphoric acid aqueous solution-ethyl acetate and processed with vortex and centrifugation to extract the target compound from plasma. And then the specificity, linearity, precision and recovery were evaluated by using apigenin as an internal standard. SD rats were employed as the animal models to obtain the concentration-time curves. The concentration-time data were analyzed by DAS 2. 1. 1. Results: The HPLC method and plasma sample pretreatment both met the requirement for the experiment. The pharmacokinetic analysis by the DAS software showed that the pharmacokinetics of RY10-4 conformed to two-compartment model and first-order dynamics. RY10-4 was eliminated mainly through the central compartment, rather than diffusing into the periphery compartment. High concentration of RY10-4 was prone to cause accumulation of RY10-4 in plasma, thereby postpone the elimination of the drug. Conclusion: The established HPLC method for RY10-4 can be performed in mild conditions and hasextensive applicability. RY10-4 has short Tmaxand rapid elimination rate and is prone to accumulate at high concentrations in rats.